期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

对“阿仑膦酸钠疗效与维生素D血清水平的相关性”一文的编后评论

原文传递
导出
摘要 本期发表了潘凌等[1]《阿仑膦酸钠疗效与维生素D血清水平的相关性》的文章,研究认为绝经后骨质疏松妇女服用阿仑膦酸钠治疗期间,血清25-羟维生素D(25-OHD)水平应该维持在50 nmol/L以上.虽然该文在研究对象选择、研究设计、药物疗效评定和数据分析等方面都需要进一步探讨和完善,但该文的结果再次说明在骨质疏松药物治疗中需要关注患者的维生素D状态.
作者 刘建民
机构地区 [
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2014年第4期-,共1页 Chinese Journal of Endocrinology and Metabolism
分类号 R580 [医药卫生—内分泌]
  • 相关文献

参考文献7

  • 1潘凌,游利,彭永德,陈瑾瑜,陈琳.阿仑膦酸钠疗效与维生素D血清水平的相关性[J].中华内分泌代谢杂志,2014,30(4). 被引量：4
  • 2Lu L,Yu Z,Pan A. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals[J].Diabetes Care,2009.1278-1283.
  • 3Xuan Y,Zhao HY,Liu JM. Vitamin D and type 2 diabetes mellitus[J].Journal of Diabetes,2013.261-267.
  • 4Adami S,Giannini S,Bianchi G. Vitamin D status and response to treatment in post-menopausal osteoporosis[J].Osteoporosis International,2009.239-244.
  • 5Olmos JM,Hernández JL,Llorca J. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate[J].Journal of Clinical Endocrinology and Metabolism,2012.4491-4497.
  • 6Ishijima M,Sakamoto Y,Yamanaka M. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women[J].Calcified Tissue International,2009.398-404.
  • 7Bischoff-Ferrari HA. How to select the doses of vitamin D in the management of osteoporosis[J].Osteoporosis International,2007.401-407.

二级参考文献9

  • 1Black DM,Cummings SR,Karpf DB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.Fracture Intervention Trial Research Group[J].The Lancet,1996.1535-1541.
  • 2Black DM,Thompson DE,Bauer DC. Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial.FIT Research Group[J].Journal of Clinical Endocrinology and Metabolism,2000.4118-4124.
  • 3Obermayer-Pietsch BM,Matin F,Mc Closkey EV. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment[J].Journal of Bone and Mineral Research,2008.1591-1600.
  • 4Antoniucci DM,Vittinghoff E,Palermo L. Vitamin D insufficiency does not affect response of bone mineral density to alendronate[J].Osteoporosis International,2009.1259-1266.
  • 5Barone A,Giusti A,Pioli G. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis:a randomized controlled trial[J].Journal of the American Geriatrics Society,2007.752-757.
  • 6Ishijima M,Sakamoto Y,Yamanaka M. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women[J].Calcified Tissue International,2009.398-404.
  • 7Antoniucci DM,Vittinghoff E,Palermo L. Vitamin D insufficiency does not affect response of bone mineral density to alendronate[J].Osteoporosis International,2009.1259-1266.
  • 8Lips P,Duong T,Oleksik A. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis:baseline data from the multiple outcones of raloxifene evaluation clinical trial[J].Journal of Clinical Endocrinology and Metabolism,2001.1212-1221.
  • 9Lu L,Yu Z,Pan A. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals[J].Diabetes Care,2009.157-163.

共引文献3

中华内分泌代谢杂志
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部